TipRanks
Advertisement
Advertisement
Johnson & Johnson price target raised to $278 from $263 at BofA
PremiumThe FlyJohnson & Johnson price target raised to $278 from $263 at BofA
9d ago
Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study
Premium
The Fly
Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study
13d ago
Johnson & Johnson reports new long-term data from Phase 2 CARTITUDE-2 study
Premium
The Fly
Johnson & Johnson reports new long-term data from Phase 2 CARTITUDE-2 study
13d ago
J&J says Caplyta Phase 3 study in bipolar I met primary endpoint
PremiumThe FlyJ&J says Caplyta Phase 3 study in bipolar I met primary endpoint
17d ago
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta
Premium
The Fly
Johnson & Johnson announces ‘positive’ results from Phase 3 trial of Caplyta
17d ago
U.S. weighs allowing most pharma licensing deals with China, Reuters says
Premium
The Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
20d ago
Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint
PremiumThe FlyContineum says MOONLIGHT-1 trial did not achieve its primary endpoint
24d ago
Johnson & Johnson reports PAPILLON study meets primary endpoint
Premium
The Fly
Johnson & Johnson reports PAPILLON study meets primary endpoint
24d ago
Nanobiotix announces updated safety, efficacy data from JNJ-1900 study
Premium
The Fly
Nanobiotix announces updated safety, efficacy data from JNJ-1900 study
24d ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―